Windlas Biotech Ltd
Windlas Biotech Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Windlas Biotech does not provide explicit future guidance but expresses optimism about growth opportunities across all three verticals: CDMO, Trade Generics, and Exports. The management refrains from giving specific future quantitative guidance on revenue, earnings, or EPS, emphasizing focus on disciplined execution and long-term strategy.
From Windlas Biotech Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Windlas Biotech does not provide explicit future guidance but expresses optimism about growth opportunities across all three verticals: CDMO, Trade Generics, and Exports.
- The company aims to continuously increase its customer base, product portfolio, and business development efforts.
- Investment in new plants (e.g., Plant 6) and expansions (injectables, oral solids) are expected to support growth, with Plant 6 commercialization anticipated in H1 FY '27.
- Management stresses the importance of disciplined execution, capability building, and operational excellence to drive sustainable growth.
- Trade Generics segment shows long-term growth potential (~40% CAGR historically), though quarterly growth rates have varied due to competitive intensity and lumpiness of institutional orders.
- The company targets strong internal growth without setting rigid numeric targets, aiming to surprise positively through execution rather than forecasts.
- Overall, growth is volume-driven, supported by expanding client relationships and diversified dosage forms.
Profitability & Margins
See what Windlas Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Plant 6 is nearing mechanical completion by end of FY '26, with expected capex around INR 50-60 crores; most of this capex is already incurred, with about INR 10 crores remaining.
- Maintenance capex continues at approximately INR 15 crores.
- Plant 6 will add capacity to reach about INR 1,000 crores revenue (excluding injectables), and injectables contribute an additional INR 100 crores capacity.
- Future capex will follow business needs and capacity utilization; expansions will be made as required.
- Plans include either acquiring strategic opportunities or investing in new dosage forms once injectable utilization approaches capacity.
- No current plans for U.S. FDA or EU GMP approvals for Plant 6, as focus remains on domestic and certain international markets.
- Management balances capex with a disciplined financial approach, willing to take debt opportunistically but maintaining cash-rich status.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Windlas Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Windlas Biotech mentioned lumpiness in institutional orders affecting quarterly Trade Generics growth.
- Some major institutional tenders/orders may slip into subsequent quarters due to timing and execution factors.
- The company focuses on execution and relationship-building to manage order flow.
- No specific quantitative details about the current or expected orderbook/pending orders were disclosed in the transcript.
- Management emphasized the unpredictable nature of institutional business and tender timing rather than fixed orderbacklog figures.
- Growth in Trade Generics is seen as having potential despite quarterly variances caused by order timing and competitive dynamics.
Windlas Biotech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹238 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Windlas Biotech Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
- Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
- Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
- Shilpa Medicare Ltd (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…
Frequently Asked Questions
What were Windlas Biotech Ltd Q3 FY26 results?
Windlas Biotech does not provide explicit future guidance but expresses optimism about growth opportunities across all three verticals: CDMO, Trade Generics, and Exports. The management refrains from giving specific future quantitative guidance on revenue, earnings, or EPS, emphasizing focus on disciplined execution and long-term strategy.
What is Windlas Biotech Ltd share price analysis?
Windlas Biotech Ltd currently shows a neutral. The stock trades at a P/E of 29.5 with a market cap of ₹1,959 Cr. Investors should review the full earnings analysis for detailed insights.
Is Windlas Biotech Ltd planning capital expenditure?
Plant 6 is nearing mechanical completion by end of FY '26, with expected capex around INR 50-60 crores; most of this capex is already incurred, with about INR 10 crores remaining. - Maintenance capex continues at approximately INR 15 crores. - Plant 6 will add capacity to reach about INR 1,000 crores revenue (excluding injectables), and injectables contribute an additional INR 100 crores capacity. - Future capex will follow business needs and capacity utilization; expansions will be made as required. - Plans include either acquiring strategic opportunities or investing in new dosage forms once injectable utilization approaches capacity. - No current plans for U.S.
Keep Windlas Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.